natgillin/translations-raw huggingface dataset:
Method according to claim 1, characterized in that during injection of said sterile washing solution the container (1) is held in a vertical position with its outlet (103) facing toward and parallel to the ground. 
Metoda u skladu sa patentnim zahtjevom 1 ili 2, naznačena time da se tokom ubrizgavanja navedene sterilne otopine za ispiranje spremnik (1) drži u vertikalnoj poziciji sa njegovim odvodom (103) usmjerenim ka i paralelnim sa tlom.
Combined organic layers are washed with brine (1x5 mL). 
Pomiješane organske slojeve ispere se slanom vodom (1 x 5 ml).
The magnetic particles can be applied in the form of a powder onto the cysts. 
Postupak prema zahtjevu 1, naznačen time što se magnetske čestice na ciste primjenjuju u obliku praška.
A compound which is represented by the following structure: or a pharmaceutically acceptable salt thereof, for use in the treatment of a disease or disorder which is selected from breast cancer, multiple myeloma, glioblastoma, and lymphoma. 
HOMO Prah x x ili njegova farmaceutski prihvatljiva sol, pri čemu se on upotrebljava u liječenju bolesti ili poremećaja koja/i je odabran/a od sljedećih: genitalno-urinarni rak, glioblastom, rak tankog crijeva i rak dojke.
Typically in the process of the invention such a laser beam may be directed at the elastomer material adjacent to the puncture site for a suitable length of time to achieve melting of the elastomer material such that through at least part of the thickness of the closure the melted elastomer material fuses to close the puncture hole. 
Tipično je da u postupku kod ovog izuma takav laserski snop može biti usmjeren na elastomerni materijal koji se nalazi uz mjesto proboda kroz prikladno vrijeme, da bi se dobilo topljenje elastomernog materijala, tako da se barem kroz dio debljine zatvarača elastomerni materijal slijepi kako bi zatvorio probušenu rupicu.
A mechanism (13) holds the body (99) of the lid with a body (94) of the hive. 
Mehanizam (13) drži tijelo (99) poklopca s tijelom (94) košnice.
The method of claim 1, wherein, when the available intra prediction mode is a DC mode, the two additional intra prediction modes include a planar mode and the vertical mode. 
Metoda prema zahtjevu 1, naznačena time da je dostupni unutarokovirni načina predviđanja DC način, dva dodatna unutarokovirna načina predviđanja su planarni 1 vertikalni način.
The pharmaceutical composition for use according to claim 1 wherein the pharmaceutical composition comprises about 1 to 4 mg of (11B,17B)-17-Hydroxy-11-[4-(methylsulphonyl)phenyl]-17-(pentafluoroethyl)estra-4,9-dien-3-one. 
Farmaceutski pripravak za uporabu prema zahtjevu 1 naznačen time što farmaceutski pripravak sadrži oko 1 do 4 mg (118,17B8)-17-hidroksi-11-[4-(metilsulfonil)fenil]-17-(pentafluoroetiljestra-4,9-dien-3-ona.
A pharmaceutical composition for parenteral administration, comprising as active ingredient a salt of claim 1, together with a pharmaceutically acceptable solvent, wherein the composition is in the form of a solution for injection, and wherein the composition contains from 0.5 to 40% by weight of the active ingredient. 
Farmaceutski sastav, naznačen time, da on kao aktivan sastojak sadrži jednu od soli prema bilo kojem zahtjevu 1 do 4, koji sastav je predviđen za parenteralno davanje i on je u obliku otopine za injekciju, koji sastav sadrži od 0,5 do 40 mas. % aktivnog sastojaka i farmaceutski prihvatljivo otapalo.
An AAV vector comprising a gene of interest for use in a method for delivering the gene to spinal cord by peripheral administration of said AAV vector to a subject in need thereof, wherein said AAV vector is a human AAV10 vector or a human AAV9 vector. 
AAV vektor koji sadrži gen od interesa za uporabu u metodi za dostavu navedenog gena od interesa kralježničnoj moždini intraperitonealnim (i.p.), intramuskularnim (i.m.) ili intravenskim (i.v.) injiciranjem, poželjno intravenskim injiciranjem, navedenog AAV vektora subjektu, pri čemu je navedeni AAV vektor:
A method as in claim 1, further comprising reacting compound E31 with hydroxylamine hydrochloride to form compound E41. 
Postupak prema patentnom zahtjevu 1, naznačen time da nadalje sadrži reakciju spoja E3' i hidroksilamin hidrohlorida kako bi se dobio spoj E4'.
In the fifth example the fat has been reduced to 70 % compared to a cake prepared with sugar, without giving up taste, appearance and texture. 
U petom primjeru količina masti smanjena je na 70 % u usporedbi s kolačem pripravljenim sa šećerom, a da time nisu bili narušeni okus, izgled ni tekstura.
The article according to claim 1, wherein the bottle is visible on at least two opposite sides of the pack. 
Proizvod (10) u skladu s barem jednim od prethodnih patentnih zahtjeva, naznačen time, da je bočica (12) vidljiva na najmanje dvije suprotne strane pakiranja (14).
Use of the antibody of any one of claims 1 to 4 for the manufacture of a medicament for treating acute lung injury. 
Uporaba protutijela iz bilo kojeg od patentnih zahtjeva 1 do 4, naznačena time, da je za proizvodnju lijeka za liječenje akutne ozljede pluća.
Description of the State of the Art 
Datum podnošenja europske prijave patenta:
In one embodiment the labeled compound has an IC50 less than about 500 µM, in another embodiment the labeled compound has an IC50 less than about 100 µM, in yet another embodiment the labeled compound has an IC50 less than about 10 µM, in yet another embodiment the labeled compound has an IC50 less than about 1 µM, and in still yet another embodiment the labeled inhibitor has an IC50 less than about 0.1 µM. 
U jednom obliku označeni spoj ima ICso manje od oko 500uM, u drugom obliku označeni spoj ima ICso manje od oko 100uM, u još jednom obliku označeni spoj ima ICsg manje od oko 10uM, u još jednom obliku označeni spoj ima ICsg manje od oko 1uM, te u slijedećem obliku označeni spoj ima ICsg manje od oko 0.1uM.
The method also provides a method of isolating an antigen presenting cell from a sample, comprising contacting the sample with a binding agent having affinity for CLEC9a and isolating one or more cells to which the binding agent is bound. 
Postupak izoliranja stanice koja predstavlja antigen, iz uzorka, naznačen time, da obuhvaća stavljanje u doticaj uzorka s protutijelom koje ima afinitet za CLEC9Ja ili s njegovim funkcionalnim fragmentom koji ima afinitet za
drying the reactive composition coated onto the substrate so as to form a basic layer (3) having a permeability such that it may adsorb and release any condensation products formed during step (d) and (e); 
(b) sušenja reaktivne kompozicije premazane na podlozi tako da nastaje osnovni sloj (3) s takvom propusnošću da može adsorbirati i osloboditi bilo kakve proizvode kondenzacije nastale tijekom koraka (d) i (6);
An example of a different use of system 10 from that installed on a harvesting implement is shown in simplified form at Figure 8. 
Jedan primjer drugačijeg korištenja sustava 10 od onog kod ugradnje na žetelačke strojeve, prikazan je, u pojednostavljenom obliku, na slici 8.
a sequence that encodes a mouse ADAM6a protein or a functional fragment thereof and a sequence that encodes a mouse ADAM6b protein or a functional fragment thereof, wherein the mouse ADAM6a protein or functional fragment thereof and the mouse ADAM6b protein or functional fragment thereof are functional in a male mouse, wherein said encoding sequences are located at a position different than an ADAM6 locus of a wild-type mouse so that, in response to exposure to an antigen, B cells of the mouse express human heavy chain variable domains expressed from a human heavy chain variable region sequence including a VH gene segment that is identical to, or a somatically hypermutated version of, VH1-2, VH1-69, VH2-26, VH2-70, or a polymorphic variant thereof; wherein said mouse lacks a functional endogenous ADAM6 gene. 
sekvencu koja šifrira mišji protein ADAM6a ili njegov funkcionalni fragment i sekvencu koja šifrira mišji protein ADAM6b ili njegov funkcionalni fragment, naznačeno time, što su mišji protein ADAM6a ili njegov funkcionalni fragment i mišji protein ADAM6b ili njegov funkcionalni protein funkcionalni u mužjaka miša, naznačeno time, što se predmetne šifrirajuće sekvence nalaze u položaju izvan lokusa ADAM6 miša divljeg tipa tako da, kao odgovor na izlaganje antigenu, B stanice miša izražavaju varijabilne domene humanog teškog lanca izražene iz sekvence varijabilne regije humanog teškog lanca uključujući segment gena VH koji je identičan ili somatski hipermutirana verzija VH1-2, VH1-69, VH2-26, VH2-70 ili njegove polimorfne varijante; naznačeno time, što predmetni miš ne posjeduje funkcionalni endogeni gen ADAM6.
It is preferred that the packaging can be closed in only one step not needing any “post squeezing” on the locking parts. 
Poželjno je da se pakiranje može zatvoriti samo u jednom koraku i da nije potrebno bilo kakvo "naknadno stiskanje" dijelova koji osiguravaju zatvaranje.
Disorder, Shared Psychotic Disorder or mania in bipolar disorder, comprising administering a therapeutically effective amount of Compound I of the invention or a salt thereof. A further embodiment of the invention relates to a method of treating positive symptoms of 5 schizophrenia comprising administering a therapeutically effective amount of Compound I or a salt thereof. Another embodiment of the invention relates to a method of treating negative symptoms of schizophrenia comprising administering a therapeutically effective amount of the Compound I or a salt thereof. 
Uporaba soli prema bilo kojem od zahtjeva 1-8 u pripremi lijeka za liječenje bolesti izabrane iz skupine koja obuhvaća shizofreniju, shizofrenoformni poremećaj, shizoafcktivni poremećaj, deluzije, kratki psihotični poremećaj, podijeljeni psihotični poremećaj i maniju kod bipolarnog poremećaja. Uporaba soli prema bilo kojem od zahtjeva 1-8 u pripremi lijeka za liječenje jednog ili vipe od pozitivnih simptoma, negativnih simptoma i depresivnih simptoma shizofrenije.
A sclerostin-binding antibody of any one of the preceding claims to which one or more effector or reporter molecule(s) is attached. 
Protutijelo za vezanje sklerostina iz bilo kojeg od prethodnih patentnih zahtjeva, naznačeno time, da su na njega vezani jedna ili više efektorskih ili reporterskih molekula.
Wind system (1) according to claim 2, characterised in that said spoiler is actuated through systems with autonomous supply. 
Vjetreni sustav (1) prema zahtjevu 2, naznačen time da spomenuta opruga bude pritisnuta zbog djelovanja napetosti spomenutog užeta (4).
The composition of claim 5, wherein the 4-1BB costimulatory signaling region comprises the amino acid sequence of SEQ ID NO: 23. The composition of claim 13, wherein the 4-1BB costimulatory signaling region is encoded by a nucleic acid sequence comprising SEQ ID NO: 17. 
(v) anti-CD19 scFv je kodiran sekvencom SEQ ID NO: 14, signalni region 4-1BB je kodiran sekvencom SEQ ID NO: 17 i signalnu domenu CD3 zeta je kodiran sekvencom SEQ ID NO: 18; ili
In some embodiments, the crosslinked amine polymer comprises the residue of an amine corresponding to Formula 2: wherein 
Farmaceutski pripravak koji sadrži umreženi aminski polimer koji veže protone i sadrži ostatak amina koji odgovara Formuli 2:
The method of item 8, wherein the HSDD is female sexual arousal disorder (FSAD). 
Pripravak za uporabu prema zahtjevu 1, naznačen time da FSD je poremećaj seksualnog uzbuđenja kod žena (FSAD).
The magnesium chloride stabilized etanercept composition of claim 5 having, on average, no more than about 10,000 subvisible particles per mL having a size greater than 5 um. 
Kompozicija stabilizirana magnezij kloridom prema patentnom zahtjevu 5 koja ima, u prosjeku, ne više od 10 000 čestica ispod granice vidljivosti po mL, koje imaju veličinu veću od 5 um.
The unit dose of claim 1, wherein the 20mg of glatiramer acetate does not form polypeptide aggregates in the 0.5ml of aqueous pharmaceutical solution. 
Jedinična doza prema patentnom zahtjevu 1, naznačena time, da 20 mg glatiramer acetata ne tvori polipeptidne aggregate u 0,5 ml vodene farmaceutske otopine.
The method of claim 27 or claim 28 characterized in that the sterilizing dose is at least 10 kGy. 
Postupak iz patentnog zahtjeva 27 ili iz patentnog zahtjeva 28, naznačen time, da doza za steriliziranje iznosi najmanje 10 kGy.
FEC decoding the time-deinterleaved L1 signaling data; 
BCH kodiranje sloja 1 odašiljanih podataka;
The compound of claim 39 wherein said cancer is breast cancer, ovarian cancer, prostate cancer, non-small cell lung cancer, colon cancer, gastric cancer, pancreatic cancer or glioma. 
Spoj prema zahtjevu 28, naznačen time da navedeni rak je rak dojke, rak jajnika, rak prostate, rak pluća ne-malih stanica, rak debelog crijeva, rak želuca, rak gušterače ili gliom.
The system of claim 2 wherein said base element (620A) comprises heating fins (622, 632) protruding from the inner face of the element. 
Sustav prema patentnom zahtjevu 2, naznačen time, da spomenuti osnovni element (620A) obuhvaća lamele za grijanje (622, 632) koje strše iz unutarnje strane elementa.
The drag head according to claim 4, wherein a width of the bed engaging surface of the heel section corresponds substantially to a width of the cutting edge. 
Usisna glava (100) sukladno zahtjevu 4, pri čemu je širina površine koja međudjeluje s ležajem (122) stražnjeg dijela (111) odgovarajuća širini reznog ruba (115).
The method of embodiment 20, wherein the orthogonal tRNA base pairs with a codon that is not normally associated with an amino acid. 
Metoda iz patentnog zahtjeva 14, gdje se ortogonalna tRNK baza spaja sa kodonom koji nije obično povezan sa aminokiselinom.
provided that when R1 is H, either and R3 come together with the carbon atoms to which they are attached to form heterocyclyl; or 
i R3 zajedno s ugljikovim atomima za koje su vezani tvore heterociklil; ili R3 je odabran od alkil, alkoksi, NR7R8, CH2OH OH, F i Cl;
that it is provided with one or more elastic bending zones, which either form a connection between the press-on portion and the lock-up body or a connection between several portions of the press-on portion; 
- dolazi s jednom ili više elastičnih savitljivih zona, koje ili formiraju vezu između samog dijela na pritisak (15) i tijela za zaključavanje (14), ili vezu između više dijelova dijela koji radi na pritisak (15);
at least one reducing monosaccharide at a final concentration from about 1% to about 5% w/v or about 1.5% to about 5% w/v or about 1.5% to about 4% w/v or about 2.5% to about 3% w/v or about 0.1% to about 0.3% w/v or 
(a) najmanje jedan redukcijski monosaharid u konačnoj koncentraciji od oko 1% do oko 5% tež./vol. ili oko 1.5% do oko 5% tež./vol. ili oko 1.5% do oko 4% tež.Avol. ili oko 2.5% do oko 3% tež.Avol. ili oko 0.1% do oko 0.3% tež./vol. ili
Use of a compound according to any one of claims 1 to 7 in the manufacture of a medicament useful for treating, preventing or ameliorating a disorder in an animal, which disorder is treated, prevented or ameliorated by activation of an opioid receptor, and wherein the disorder is preferably selected from the group consisting of pain, diarrhea, or emesis. 
Uporaba spoja prema Formuli I naznačena time da je za proizvodnju lijeka za liječenje, sprečavanje ili ublažavanje poremećaja kod životinje, koji poremećaj se liječi, sprečava ili ublažava pomoću aktivacije opioidnog receptora, te gdje je poremećaj bol, pri čemu spoj sa formulom I je: [image] gdje A je aril ili heteroaril;
Plates were returned to the incubator for 4hrs and then 20µl of 20% formaldehyde solution in PBS was added to each well and the plate was left at room temperature for 30 minutes. 
Pločice se vrate u inkubator na 4 sata, nakon čega se HR P20070113 T3 u svaki bunarić mikrotitarske pločice doda 20 ul 20 %-tne totopine formaldehida u PBS-u i ostavi pri sobnoj temperaturi 30 minuta.
Optically active compounds can also be prepared from optically active starting materials. 
Optički aktivni spojevi mogu se pripraviti 1 iz optički aktivnih startnih materijala.
In an embodiment, the functional filler is present in an amount equal to or greater than about 10% by weight of the waste polymer, for example, equal to or greater than about 20% by weight, for example, equal to or greater than about 30% by weight, for example, equal to or greater than about 40% by weight, for example, equal to or greater than about 50% by weight or, for example, equal to or greater than about 60% by weight. 
"oblogu, koja sadrži prvi spoj, koji sadrži krajnju propanskokiselinsku skupinu ili etilensku skupinu, uz jednu ili dvije susjedne karbonilne skupine; i miješanju potrošenog otpadnog polimera s funkcionalnim punilom kako bi se dobilo reciklirani polimer, gdje funkcionalno punilo dolazi u količini jednakoj ili većoj od 10%, težinski, otpadnog polimera.
An isolated antibody or antigen-binding fragment thereof specifically binding to amino acids 1 - 85 of SEQ ID NO:1, wherein said antibody or antigen-binding fragment thereof is internalized following binding to C4.4a expressing cells, and wherein said antibody or antigen-binding fragment thereof comprises the variable heavy chain CDR sequences: 
Izolirano protutijelo ili njegov fragment koji veže antigen koje se specifično veže na amino kiseline 1 -85 iz SEQ ID NO:l, naznačeno time da navedeno protutijelo ili njegov fragment koji veže antigen je je intemalizirano nakon vezanja na stanice koje eksprimiraju C4.4a, 1 pri čemu protutijelo ili njegov fragment koji veže antigen sadrži varijabilnu sekvencu teškog lanca CDR:
contacting the sample with AB-aggregates or with particles comprising AB-aggregate like surfaces and allowing the AB-specific antibodies to bind to the AB-aggregates, and 
- - stavljanje u doticaj uzorka s AB-agregatima ili s kuglicama koje imaju AB-agregate imobilizirane na svojoj površini, te dopuštanje AB-specifičnim protutijelima da se vežu na AB-agregate, i
Garment, according to claim 1, characterized in that the content of polyethylene covering the synthetic fibres is in the range of 0,1% and 0,3% in weight in respect of the total weight of the garment. 
Odjevni predmet u skladu s patentnim zahtjevom 1, naznačen time, da je sadržaj polietilena koji pokriva sintetička vlakna u rasponu od 0,1 % do 0,3 % težine u odnosu na ukupnu težinu odjeće.
The method of Claim 1, wherein the organic diepoxide is 4-vinylcyclohexene diepoxide; or wherein (a) is triptolide and (b) is 4-vinylcyclohexene diepoxide. 
Sastav prema zahtjevu 1, naznačen time što diterpenoid epoksid (a) je triptolid i organski diepoksid (b) je 4-vinilcikloheksen diepoksid (VCD).
The method of paragraph 1, wherein said at least a portion of said CRISPR locus of said parent bacterial strain and at least a portion of said modified CRISPR locus of said bacteriophage resistant variant strain are compared by sequencing at least a portion of said CRISPR locus and at least a portion of said modified CRISPR locus. 
Postupak prema zahtjevu 1, naznačen time da se navedeni barem dio navedenog CRISPR lokusa navedenog matičnog bakterijskog soja i barem dio navedenog modificiranog CRISPR lokusa navedenih varijanti sojeva rezistentnih na bakteriofage uspoređuju sekvenciranjem barem dijela navedenog CRISPR lokusa i barem dijela navedenog modificiranog CRISPR lokusa.
In another aspect, B is (CH2). where n is an integer ranging from 0-10, or B is an unsaturated carbon chain of 2-10 carbons. 
B je (CH>), gdje je n cijeli broj u rasponu od 0-10, ili je B nezasićemi lanac ugljika s 2-10 ugljika; i
was treated with thionyl chloride (66 ml., 0.90 mole) and the resulting solution heated at reflux for 75 minutes, with provision made for trapping HCI gas given off from the refluxing reaction solution. 
tretira se sa tionilkloridom (66 ml., 0.90 mola) i dobivena otopina zagrijava se na refluksu 75 minuta, pri čemu se osigura uklapanje HC1 plina iz refluksirajućeg reakcijskog otopine.
Acetyl-leucine, or a pharmaceutically acceptable salt thereof, for use in a method of reversing progression of a LSD or one or more symptoms associated with a LSD over time, wherein the method comprises administering a therapeutically effective amount of the acetyl-leucine to the subject in need thereof for a duration chosen from at least about 3 months, at least about 6 months, at least about 1 year, at least about 2 years, and at least about 5 years. 
Acetil-leucin, ili njegova farmaceutski prihvatljiva sol, za uporabu prema zahtjevu 1 kako bi se unazadila progresija LSD-a ili jednog ili više simptoma povezanih s LSD-jem tijekom vremena, pri čemu uporaba sadrži primjenu terapeutski djelotvorne količine acetil-leucina na subjektu kojemu je to potrebno kroz razdoblje odabrano od barem oko 3 mjeseca, barem oko 6 mjeseci, barem oko 1 godine, barem oko 2 godine i barem oko 5 godina.
The procedure for obtaining the vaccine composition according to Claim 14, wherein the conjugated protein is purified by a ultrafiltration/diafiltration method using a membrane having a pore size of 100 kDa. 
Sastav cjepiva prema zahtjevu 1, koji kao aktivni sastavni element sadrži konjugirani protein hrEGF-rP64K, naznačen time, da se spomenuti sastav cjepiva purificira postupkom prema bilo kojem zahtjevu od 9 do 13.
An oat-based B-glucan concentrate, characterized in that its B-glucan content is 30 to 40%, and it is composed of B-glucan of the oat aleurone, protein content is 22 to 35%, starch content is at most 15%, preferably at most 10%, fat content is less than 3.5%, preferably less than 2%, volume-average particle size is 160 to 280 µm, and at least 95% of the particles are between 35 and 1,000 µm, and that it is obtained from step (c) of the method of claim 1. 
Koncentrat B-glukana na bazi zobi, naznačen time što sadržaj B-glukana je 30 do 40%, i sastoji se od B-glukana iz aleurona zobi, sadržaj proteina je 22 do 35%, sadržaj škroba je najviše 15%, poželjno najviše 10%, sadržaj masti je manji od 3.5%, poželjno manji od 2%, volumno-prosječna veličina čestica je 160 do 280 µm, i barem 95% čestica je između 35 i 1,000 µm, i dobiva se iz koraka (c) postupka prema zahtjevu 1.
The composition of claim 1, wherein the hydrophilic organic solvent is at least one selected from the group consisting of N,N-dimethylacetamide, dimethylsulfoxide, Y-butyrolactone, N-methyl-2-pyrrolidone and cyclohexanone. 
Pripravak u skladu s patentnim zahtjevom 1, naznačen time, da je hidrofilno organsko otapalo barem jedno od izabranih iz skupine koju čine N,N-dimetilacetamid, dimetilsulfoksid, g-butirolakton, N-metil-2-pirolidon i cikloheksanon.
A combination comprising: 
Kombinacija od
The composition according to claim 1, wherein said effervescent excipient component further comprises a pH adjusting substance. 
Pripravak prema zahtjevu 1, naznačen time da navedena komponenta šumeće pomoćne tvari nadalje sadrži tvar za prilagođavanje pH.
7 shows a schematic curved section of a part of the circumferential wall provided by the housing or locking element 18 and illustrates the functioning of the first/second locking means. 
Slika 7 prikazuje shematski zakrivljeni presjek dijela obodne stijenke opremljene s kućištem ili s elementom za zabravljivanje 18 1 ona prikazuje funkciju prvog/drugog sredstva za zabravljivanje.
Advantageously, the fibre cement material is heated up to the temperature of said hot zone in 1 to 5 seconds, preferably in less than 2 seconds. 
Postupak prema bilo kojem od patentnih zahtjeva 1 do 7, naznačen time što se materijal od vlaknastog cementa zagrijava tijekom manje od 2 sekunde na navedenu temperaturu od najmanje 800*C.
The method of claim 8, wherein the immune response is cross-protective against a heterologous influenza virus. 
Sastav cjepiva za uporabu prema zahtjevu 7, pri čemu je zaštitni imunološki odgovor križno-zaštitni protiv heterolognog virusa gripe.
being 65 years of age or older; 
(1) ima 65 godina ili stariji;